Joseph Chin on Muck Rack

Joseph Chin

Verified
Malaysia
As seen in: The Star (Malaysia), Educational Studies, BMC Cancer, JAMA Oncology, Mississauga.com, European Urology, EMJ- European Medical Journal, Canadian Urological Association Journal
Star Biz multimedia editor
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Joseph

Contact Joseph, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database

|
By Joseph Chin 
| European Urology
Huynh MJ, Eng L, Ngo LH, et al To read this article in full you will need to make a payment Subscribe to European Urology References Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 396: 1422-1431 Second primary cancers following radiotherapy for prostate cancer: How many are actually due to the radiotherapy?. Can Urol Assoc J.
Open in Who Shared Issue with article?

A Canadian center’s experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities

|
By Joseph Chin , Max Peters, J. Jesus Cendejas-Gomez
| Canadian Urological Association Journal
Abstract Salvage radical prostatectomy for localized radio-recurrent prostate cancer has historically been associated with significant morbidity. Prospectively collected data long-term data on salvage whole-gland cryoablation and, to a lesser extent, high-intensity focused ultrasound (HIFU), have shown they are viable treatment alternatives.
Open in Who Shared Issue with article?

The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER). | BMC Cancer | Full Text

|
By Lucas C. Mendez, Lucas Méndez, David Laidley, Jose Gomez, José Gómez , Joseph Chin , Jonathan D. Thiessen, Douglas Hoover, Joelle Helou, David P. D’Souza, Jane Bayani, Glenn Bauman, Aneesh Dhar, Madeleine Moussa, T-Y Lee, Kathleen Surrey, Vikram Velker, Rohann J. Correa
| BMC Cancer
Inclusion and exclusion criteria Patients with suspected ILF after radiation will be recruited. Patients must have a BCF per Phoenix criteria at least two years after initial prostate cancer treatment, an intra-prostatic lesion with PSMA PET avidity (Standard Uptake Value (SUV) of 3.0 or greater on a diagnostic PSMA PET/CT), and no evidence of extra prostatic disease.
Open in Who Shared Issue with article?
See all 2,723 licensed articles (2,724 Total)

Actions

Share this page

Get in touch with Joseph

Contact Joseph, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified